Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Inclusion Criteria

• •Age \>= 18 years
• •English speaking
• •Cancer diagnosis of any tumor type with chemotherapy-induced neuropathy
• •At least 4 out of 10 severity of neuropathy pain and/or tingling
• •Stable for at least 7 days prior to registration on medications for neuropathy, if any are being used
• •Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
• •Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only
• •* NOTE: If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
• •Able to provide written informed consent
• •Ability to complete questionnaire(s) by themselves or with assistance
• •No evidence of residual cancer
• •Platelet count \> 100,000/mm\^3 (following completion of chemotherapy)
• •Absolute neutrophil count (ANC) \>= 1,000/mm\^3 (following completion of chemotherapy)
• •Hemoglobin \> 11 g/dL (following completion of chemotherapy)
• •Serum transaminase (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) =\< 1.2 x upper limit of normal (ULN) (following completion of chemotherapy)
• •Alkaline phosphatase =\< 1.2 x ULN (following completion of chemotherapy)
• •Serum creatinine =\< 1.2 x ULN (following completion of chemotherapy)